Lmb-2
Adult T-Cell Leukemia (ATL)
National Cancer Institute (NCI)antibody_drug_conjugatePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 95/ 100
Competitive context
38 Active assets in the Adult T-Cell Leukemia (ATL) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide John Reneau | Phase 4 | BBB |
DEXAMETHASONE The First Affiliated Hospital of Soochow University | Phase 2 | BBB |
Fludarabine John Reneau | Phase 2 | BBB |
ETOPOSIDE National Cancer Institute (NCI) | Phase 2 | BBB |
cc-5013 National Cancer Institute (NCI) | Phase 2 | BBB |
View all 50 →
Same molecule, other indications
Lmb-2 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →